JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10.856 60.328
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-8.2M 184M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank -2-

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

26. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Dollar's Strength -- Market Talk

26. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.